Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer

@article{Borazanci2014NabpaclitaxelAG,
  title={Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer},
  author={Erkut Borazanci and Daniel D. Von Hoff},
  journal={Expert Review of Gastroenterology \& Hepatology},
  year={2014},
  volume={8},
  pages={739 - 747}
}
Adenocarcinoma of the pancreas or pancreatic cancer as we will refer to it here, is a cancer of poor prognosis with a high mortality, particularly in the advanced or metastatic setting. Until 2011 and the Phase III results of FOLFIRINOX, standard treatment options were limited to gemcitabine. Combination therapy had shown either a lack of or very limited improvement versus monotherapy with gemcitabine. With the positive results of the MPACT study in 2013 showing improved survival with nab… 
Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis
TLDR
Combination chemotherapy using gemcitabine and nab-paclitaxel was effective in a PDAC patient undergoing hemodialysis, and early dose modification was needed for this patient because of severe adverse events.
Ask ACCC's Community Resource Centers: Pancreatic Cancer
TLDR
Current front-line treatment options in advanced or metastatic pancreatic cancer involve the use of combination chemotherapy regimens, such as 5-FU, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or nab-paclitaxel plus gemcitabine.
Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
TLDR
The double-edged sword of its therapeutic effects might promote tumor progression and undermine patient survival, so achieving a balance between stromal abundance and depletion might be the further of stroma-targeting therapy.
Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
TLDR
All the evidence for the stages in which the cancer is not primarily resectable with surgery, known as borderline resectables or locally advanced unresectable, is evaluated.
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
TLDR
An updated and critical overview about the role of nab-paclitaxel in PDAC treatment based on the latest advances in preclinical and clinical research and about future implications in the light of current clinical ongoing trials are provided.
Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma
TLDR
FOLFIRINOX with patient-tailored dose adaptations seems to offer better results in patients with advanced PC, with results in a macroscopic R0R1 in 61% of patients with initially unresectable disease.
Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
TLDR
This review summarizes the molecular features of this refractory disease while focusing on the recent clinical and experimental findings on pancreatic cancer, and discusses the data supporting current standard clinical outcomes, and offers conclusions that may improve the management of pancreaticcancer in the future.
Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study
TLDR
Iinotecan combined with oxaliplatin and S-1 is a safe and effective treatment for metastatic pancreatic adenocarcinoma, and any toxicities are mild to moderate and tolerable.
...
1
2
3
4
...

References

SHOWING 1-10 OF 52 REFERENCES
Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
TLDR
The preclinical and clinical progress in the development of nab-paclitaxel for the treatment of metastatic PC is provided, with results showing improvement in response rate, progression-free survival, and overall survival compared to single agent gemcitabine.
Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer.
381 Background: The recent results of the phase III trial MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) demonstrated an improvement in progression free survival, overall response rate,
Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC).
TLDR
A 52 year old female with locally advanced pancreatic cancer with elevated CA19-9 at diagnosis who received GEM + nab-P followed by GEM based chemoradiation who underwent surgical resection despite persistent stable disease on radiographic studies and was found to have complete pathologic response.
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
TLDR
In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased.
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
TLDR
The regimen of nab-paclitaxel plus gemcitabine has tolerable adverse effects with substantial antitumor activity, warranting phase III evaluation.
Combinational therapy: new hope for pancreatic cancer?
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
  • M. Moore, D. Goldstein, W. Parulekar
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
To the authors' knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine.
The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer
TLDR
In the era of biologic and molecularly targeted agents, the success of nab-paclitaxel in recalcitrant pancreatic cancer is a timely reminder of the importance and relevance of pharmacology and novel drug delivery technology in the development of anticancer drugs.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
TLDR
It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
...
1
2
3
4
5
...